Scandion Oncology A/S has been granted an Impact Voucher of 14.999 EUR from Biopeople, Denmark’s Life Science Cluster, as partner in the Boost4Health Interreg project of leading bioregions in North-West Europe. The Impact Voucher supports SCO-101 development in relation to anti-estrogen resistance in breast cancer. The selection committee of Boost4Health based their decision on the benefit of providing access to European partners and markets and to the advancement of product validation for Scandion Oncology A/S.
CSO, Jan Stenvang says: “We are very proud to receive this funding and acknowledgement from the EU Boost4Health Interreg project. The grant will allow us to speed up collaborations with some of the leading scientist in Europe and thereby further expand the development of SCO-101 as a drug that reverses resistance to anti-cancer compounds”.
Scandion Oncology A/S is a biotechnology company founded in 2017 for the purpose of addressing and tackling one of the greatest challenges in modern oncology – the effective treatment of cancer which contains drug resistant cell clones or which has developed resistance to a previously prescribed anti-cancer drug. In preclinical animal studies, the company’s leading candidate drug, SCO-101, has been found to significantly enhance the efficacy of certain standard cancer treatments when given in combination. Even more importantly, SCO-101 has in in vitro studies shown to restore chemotherapy and anti-estrogen sensitivity in resistant cancer cells (www.scandiononcology.com).
Biopeople is Denmark’s Life Science Cluster located at the University of Copenhagen. Biopeople is part of the Danish infrastructure for innovation, which is established and co-funded by the Ministry of Higher Education and Science (innovationsnetværk). Biopeople is partner in the Boost4Health programme (www.biopeople.eu).
Boost4Health provides practical and financial support to small and medium-sized enterprises (SMEs) who wish to explore their international growth potential. For instance, to expand their international network, find expertise abroad through e.g. collaboration with service providers, or to validate products in another market. The aim of Boost4Health is to accelerate the growth of SMEs, create awareness of the market opportunities within North-West Europe and as a long-term effect to create more jobs in the life sciences sector. Boost4Health is part of the North-West Europe Interreg programme funded by the European Regional Development Fund with a budget of 4.4 mEUR (www.boost4health.eu).
For additional information about Biopeople, please contact:
For additional information regarding Scandion Oncology, please contact:
Nils Brünner, CEO
Phone: +45 26 14 47 08